生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Jaguar Health
Announces Import of Coca Leaf From Peru by Joint Venture
Magdalena Biosciences
for Research in Treating
ADHD
2023-09-21
·
BioSpace
临床3期
并购
Magdalena Biosciences
is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Authority SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 /
Jaguar Health, Inc.
(NASDAQ:JAGX) ("
Jaguar
") today announced that
Magdalena Biosciences, Inc.
("Magdalena"), the joint venture recently formed by
Jaguar
and
Filament Health Corp.
(OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("
Filament
" or "
Filament Health
"), successfully completed an import of coca leaf to a
Filament
facility (
Psilo Scientific
) in Canada. Image of coca leaves. © Steven R. King Magdalena was founded on a mission to develop novel, natural prescription medicines derived from plants for mental health indications including
attention-deficit/hyperactivity disorder (ADHD)
,
depression
, and
anxiety
in adults. The coca leaf imported from Peru will be used for initial research purposes to look at these and other neuropsychiatric indications. The import of coca leaves was authorized by the Peruvian Health Authority - Dirección General de Medicamentos Insumos y Drogas (DIGEMID) - and acquired from the Empresa Nacional de la Coca (ENACO), which is the only company in Peru authorized to collect, distribute, and export coca leaves and their derived products. "We are grateful to the Peruvian government for their cooperation, and look forward to Magdalena initiating its pioneering research into the potential benefits of coca for
ADHD
,
depression
, and
anxiety
," said Steven King, PhD,
Jaguar
's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer and an Advisor to Magdalena, who facilitated the relationship with ENACO on behalf of Magdalena and
Psilo Scientific
. "In traditional medicine, coca leaves are utilized as a remedy for a wide variety of conditions, ranging from alleviating
oral pain
,
digestive maladies
, hunger,
altitude sickness
, as well as
muscular and skeletal aches
. Many commonly used neuropsychiatric medications have side effects such as personality changes or
sedation
. With centuries of use by Indigenous healers and traditional psychiatrists, plant-derived medicines offer potential new mechanisms of action for treating
mental disorders
while being potentially safer than the small molecule drugs that may have 'off target' effects." "I am delighted that
Magdalena Biosciences
is proceeding with initial research on the therapeutic potential of coca leaf for
ADHD
,
depression
, and
anxiety
and I believe there will be benefits at multiple levels for Andean nations and for patients around the world if coca leaf products become available to help manage a diversity of medical conditions," said Wade Davis, Ph.D. Dr. Davis, an adviser to Magdalena and a member of the Scientific Strategy Team for
Jaguar
's
Entheogen Therapeutics
Initiative (ETI), is an ethnobotanist, anthropologist, bestselling author, and former National Geographic Explorer-in-Residence. Once considered a childhood disorder,
ADHD
is now acknowledged to persist into adulthood in approximately 50-65% of individuals, and impacts an estimated 5.2% of U.S. adults aged 18-44. Treatment of
ADHD
remains challenging. An estimated 20-50% of adult patients either are non-responders to stimulants or cannot tolerate the adverse effects of current therapeutics. New therapeutics in development for the global
ADHD
market, which is projected to reach a value of US$18.69 billion by 2030 according to a report by
Grand View Research
, show promise but continue to have significant side effects.
Social anxiety
and
depression
are common co-morbidities of
ADHD
.
Social anxiety
, typified as extreme fear in social settings and debilitating social withdrawal, often has an age of onset during late childhood. Common treatments include medication and psychotherapy. Unmet needs in the treatment of
anxiety disorders
include the need for more effective, rapidly acting, and better tolerated medications. Botanical drugs offer these potential advantages. Current medications for treatment of
depression
are often ineffective as well as personality altering. Unmet needs in
depression
include medications with greater overall effectiveness as well as improvement in the patient's ability to function day to day. Botanical drugs have the potential to meet these needs while also offering an improved safety profile. "We are pleased to partner with
Filament Health
(
Psilo Scientific
) and Magdalena to facilitate this landmark import," said Silveria Dongo Gonzales, Technical Director of ENACO. Richard Caballero, Director of Industrial Commercialization at ENACO, added, "We appreciate
Filament
's and Magdalena's efforts to ensure that they have fully followed all of the requirements of ENACO, and that they are working through the process to obtain full compliance with the Nagoya Protocol in Peru." Magdalena and
Psilo Scientific
are in the process of seeking full Nagoya Protocol compliance at this time in Peru. The Nagoya Protocol is an international agreement that ensures sharing of benefits arising from the utilization of genetic and indigenous knowledge in a fair and equitable manner. ABOUT MAGDALENA BIOSCIENCES
Jaguar Health, Inc.
and
Filament Health Corp.
formed
Magdalena Biosciences, Inc.
as a joint venture in 2023 to develop novel, natural prescription medicines derived from plants for mental health indications including
attention-deficit/hyperactivity disorder (ADHD)
,
depression
and
anxiety
in adults. Boulder, Colorado-based One Small Planet, founded by Will Peterffy, has committed to funding of US$1,000,000. The goal of the collaboration is to extend the botanical drug development capabilities of
Jaguar
and
Filament
in order to develop pharmaceutical-grade, standardized drug candidates for
mental health disorders
. About the
Jaguar Health Family of Companies
Jaguar Health, Inc.
(
Jaguar
) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as
chronic debilitating diarrhea
, urgency, and
bowel incontinence
.
Jaguar
family company
Napo Pharmaceuticals
focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals
'
crofelemer
drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of
chemotherapy-induced overactive bowel (CIOB)
in adults with
cancer
on targeted therapy.
Jaguar
family company
Napo Therapeutics
is an Italian corporation
Jaguar
established in Milan, Italy in 2021 focused on expanding
crofelemer
access in Europe and specifically for orphan and/or rare diseases.
Jaguar Animal Health
is a
Jaguar
tradename.
Magdalena Biosciences
, a joint venture formed by
Jaguar
and
Filament Health Corp.
that emerged from
Jaguar
's
Entheogen Therapeutics
Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about
Jaguar Health
, please visit . For more information about
Napo Pharmaceuticals
, visit . For more information about
Napo Therapeutics
, visit napotherapeutics.com. For more information about
Magdalena Biosciences
, visit magdalenabiosciences.com. Visit Jagaur on LinkedIn: Visit Jagaur on X: Visit Jagaur on Instagram: Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions.
Jaguar
has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond
Jaguar
's control. Except as required by applicable law,
Jaguar
does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Info: hello@jaguar.health
Jaguar
-JAGX SOURCE:
Jaguar Health, Inc.
View source version on accesswire.com:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Jaguar Health, Inc.
Magdalena Biosciences, Inc.
Magdalena Biosciences, Inc.
[+6]
适应症
大便失禁
高原反应
镇静
[+11]
靶点
-
药物
Crofelemer
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务